"We are the Inland Northwest’s largest and longest standing urology practice. We take pride in communicating with and educating our patients about their urologic conditions and offering state-of-the-art treatment options. We believe that patient partnership is essential to selecting the best treatment option for each patient."

During the past decade, Spokane Urology conducted 10 clinical trials. In the 10-year time frame, 10 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 10 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Spokane Urology" #1 sponsor was "Janssen Research & Development, LLC" with 4 trials, followed by "CG Oncology, Inc." with 2 trials sponsored, "Arquer Diagnostics Ltd" with 1 trials sponsored, "Myovant Sciences GmbH" with 1 trials sponsored and "UroGen Pharma Ltd." with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Spokane Urology" #1 collaborator was "Merck Sharp & Dohme LLC" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Spokane Urology" are "Urinary Bladder Neoplasms" (3 trials), "Bladder Cancer" (2 trials), "Androgen Resistant Prostatic Cancer" (1 trials), "Metastatic Castration-resistant Prostate Cancer" (1 trials) and "Non Muscle Invasive Bladder Cancer" (1 trials). Many other conditions were trialed in "Spokane Urology" in a lesser frequency.

Most popular intervention types in "Spokane Urology" are "Drug" (7 trials), "Biological" (5 trials), "Other" (2 trials), "Diagnostic Test" (1 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Cetrelimab" (3 trials), "TAR-200" (3 trials), "CG0070" (2 trials), "Relugolix" (2 trials) and "n-dodecyl-B-D-maltoside" (2 trials). Other intervention names were less common.

The vast majority of trials in "Spokane Urology" are 7 trials for "All" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "Spokane Urology". undefined are not yet recruiting, 6 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Spokane Urology, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Spokane Urology, 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".